Programmed death-1 ligand-1 (PDL1) expression is associated with the prognosis of patients with stage II/III gastric cancer

Anticancer Research

Volumn 35, Issue 10, 2015, Pages 5369-5376

  Tamura, Tatsuro ^a   Ohira, Masaichi ^a   Tanaka, Hiroaki ^a   Muguruma, Kazuya ^a   Toyokawa, Takahiro ^a   Kubo, Naoshi ^a   Sakurai, Katsunobu ^a   Amano, Ryosuke ^a   Kimura, Kenjiro ^a   Shibutani, Masatsune ^a   Maeda, Kiyoshi ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastric cancer; Programmed cell death 1 (PD1); Programmed death 1 ligand 1 (PDL1)

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL DENSITY; CELL INFILTRATION; CLINICAL FEATURE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STOMACH CANCER; SURVIVAL RATE; TUMOR DIFFERENTIATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84942794932     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29: 4387-4393, 2011.
2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J and Kang YK: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase III, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
3. Keir ME, Butte MJ, Freeman GJ and Sharpe AH: PD1 and its ligands in tolerance and immunity. Annual review of immunology 26: 677-704, 2008.
4. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS,Senupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC and Kwon ED: Tumor B7-H1 is associated with poor prgnosis in renal cell carcinoma patients with long-term follow-up. Cancer research 66: 3381-3385, 2006.
5. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E and Chen L: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature medicine 8: 793-800, 2002.
6. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, Tsushima F, Otsuki N, Yagita H, Azuma M and Nakajima Y: Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 11: 2947-2953, 2005.
7. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A and Wigginton JM: Safety and activity of anti-PDL1 antibody in patients with advanced cancer. The New England journal of medicine 366: 2455-2465, 2012.
8. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM and Sznol M: Safety, activity, and immune correlates of anti-PD1 antibody in cancer. The New England journal of medicine 366: 2443-2454, 2012.
9. Iwauchi T, Tanaka H, Yamazoe S, Yashiro M, Yoshii M, Kubo N, Muguruma K, Sawada T, Ohira M and Hirakawa K: Identification of HLA-A∗2402-restricted epitope peptide derived from ERAS oncogene expressed in human scirrhous gastric cancer. Cancer science 102: 683-689, 2011.
10. Ito G, Tanaka H, Ohira M, Yoshii M, Muguruma K, Kubo N, Yashiro M, Yamada N, Maeda K, Sawada T and Hirakawa K: Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Experimental and therapeutic medicine 3: 925-930, 2012.
11. Japanese Gastric Cancer Association: Japanese gastric cancer treatment guidelines 2010(ver.3).Gastric Cancer 14: 113-123, 2011.
12. Topalian SL, Drake CG and Pardoll DM: Targeting the PD1/B7-H1(PDL1) pathway to activate anti-tumor immunity. Current opinion in immunology 24: 207-212
13. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, Zuber M, Muraro MG, Amicarella F, Cremonesi E, Heberer M, Iezzi G, Lugli A, Terracciano L, Sconocchia G, Oertli D, Spagnoli GC and Tornillo L: Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 49: 2233-2242, 2013.
14. Geng Y, Wang H, Lu C, Li Q, Xu B, Jiang J and Wu C: Expression of costimulatory molecules B7-H1, B7-H4 and FOXP3(+) Tregs in gastric cancer and its clinical significance. International journal of clinical oncology 20: 273-281, 2015.
15. Muenst S, Schaerli AR, Gao F, Daster S, Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE, Weber WP and Soysal SD: Expression of programmed death ligand 1 (PDL1) is associated with poor prognosis in human breast cancer. Breast cancer research and treatment 146: 15-24, 2014.
16. Wang L, Ma Q, Chen X, Guo K, Li J and Zhang M: Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma. World journal of surgery 34: 1059-1065, 2010.
17. Yoshii M, Tanaka H, Ohira M, Muguruma K, Iwauchi T, Lee T, Sakurai K, Kubo N, Yashiro M, Sawada T and Hirakawa K: Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomach. British journal of cancer 106: 1668-1674, 2012.
18. Yoshii M, Tanaka H, Ohira M, Muguruma K, Sakurai K, Kubo N, Yashiro M, Sawada T and Hirakawa K: Association of MHC class I expression and lymph node metastasis of gastric carcinoma. Hepato-gastroenterology 60: 611-615, 2013.
19. Saito H, Kuroda H, Matsunaga T, Osaki T and Ikeguchi M: Increased PD1 expression on CD4+ and CD8+ T-cells is involved in immune evasion in gastric cancer. Journal of surgical oncology 107: 517-522, 2013.
20. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L and Investigators K: Pembrolizumab for the treatment of non-small-cell lung cancer. The New England journal of medicine 2015.